MBX Biosciences, Inc.

MBX
$30.99 (+ $1.12 + 3.75%)
Last updated: 2026-06-10 22:29 UTC
MBX Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS55287L1017
CUSIP55287L101
Market Price30.99
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E Ratio4.19
EPS7.67
Market Cap$1.4B
Book Value8.67
Price to Book3.705
BetaN/A
52w High35.55
52w Low4.81
Next Earnings DateN/A

MBX Biosciences, Inc. trades under ticker MBX on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US55287L1017, CUSIP 55287L101. Also searched as MBX Biosciences.

Related researchMBX stock priceMBX share price55287L101MBX Biosciences stockMBX Biosciences share price
About the Company
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Price History